[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[2] Ministry of Health of the People's Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J]. J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
|
[3] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):114-125.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):114-125.
|
[4] QI J,GAO ZQ,LIU SC,et al. Value of diffusion-weighted magnetic resonance imaging combined with serum tumor markers in diagnosing early primary liver cancer[J]. Chin J Med Offic,2018,46(9):1057-1058.(in Chinese)齐杰,高战强,刘树昌,等.磁共振扩散加权成像联合血清肿瘤标志物对诊断早期原发性肝癌价值分析[J].临床军医杂志,2018,46(9):1057-1058.
|
[5] DANIELE B,BENCIVENGA A,MEGN AS,et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma[J]. Gastroenterology,2004,127(5 Suppl 1):s108-s112.
|
[6] TATEISHI R,SHIINA S,YOSHIDA H,et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers[J]. Hepatology,2006,44(6):1518-1527.
|
[7] GUPTA S,BENT S,KOHLWES J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis[J]. Ann Intern Med,2003,139(1):46-50.
|
[8] MARRERO JA,FENG Z,WANG Y,et al. Alpha-fetoprotein,des-gamma carboxyprothrombin,and lectin-bound alphafetoprotein in early hepatocellular carcinoma[J]. Gastroenterology,2009,137(1):110-118.
|
[9] LIU XE,DESMYTER L,GAO CF,et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus[J]. Hepatology,2007,46(5):1426-1435.
|
[10] FANG M,ZHAO YP,ZHOU FG,et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma[J]. Int J Cancer,2010,127(1):148-159.
|
[11] WANG L,VANHOOREN V,DEWAELE S,et al. Alteration of liver n-glycome in patients with hepatocellular carcinoma[J].Open J Gastroenterol,2012,2(1):1-8.
|
[12] KOBATA A,AMANO J. Altered glycosylation of proteins produced by malignant cells,and application for the diagnosis and immunotherapy of tumours[J]. Immunol Cell Biol,2005,83(4):429-439.
|
[13] DENNIS JW,GRANOVSKY M,WARREN CE. Glycoprotein glycosylation and cancer progression[J]. Biochim Biophys Acta,1999,1473(1):21-34.
|
[14] WARD DG,CHENG Y,N’KONTCHOU G,et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis[J]. Br J Cancer,2006,94(2):287-292.
|
[15] CAO X,LIU XE,ZHUANG H. Serum N-glycome profiling as markers for diagnosis of liver fibrosis/cirrhosis and hepatocellular carcinoma induced by hepatitis B/C viruses[J]. Chin J Viral Dis,2019,9(3):228-235.(in Chinese)曹曦,刘学恩,庄辉.血清N糖组学标志物诊断乙型和丙型肝炎病毒相关肝纤维化、肝硬化和肝细胞癌[J].中国病毒病杂志,2019,9(3):228-235.
|
[16] VANHOOREN V,LIU XE,FRANCESCHI C,et al. N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing[J]. Mech Ageing Dev,2009,130(1-2):92-97.
|
[17] ZHU YP,LU GF,HUANG LN,et al. Value of serum CA125,CA199,CEA,and AFP in differential diagnosis of hepatitis and liver cirrhosis[J]. Shandong Med J,2019,59(1):46-48.(in Chinese)朱壹澎,卢高峰,黄丽娜,等.血清CA125、CA199、CEA、AFP检测在肝炎与肝硬化鉴别诊断中的价值[J].山东医药,2019,59(1):46-48.
|